PARP and PARG Inhibitors—New Therapeutic Targets in Cancer Treatment

• Published in: Pathology oncology research Vol. 16; no. 4; pp. 469 - 478
• Main Authors: Fauzee, Nilufer Jasmine Selimah, Pan, Juan, Wang, Ya-lan
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.12.2010; Springer Nature B.V
• Subjects: Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Enzyme Inhibitors - pharmacology; Enzyme Inhibitors - therapeutic use; Glycoside Hydrolases - antagonists & inhibitors; Glycoside Hydrolases - metabolism; Humans; Immunology; Medical research; Molecular Targeted Therapy - methods; Neoplasms - drug therapy; Neoplasms - enzymology; Oncology; Pathology; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases - metabolism; Year 2000; PARP; PARG; PARP inhibitors; PARG inhibitors
• ISSN: 1219-4956; 1532-2807
• DOI: 10.1007/s12253-010-9266-6

Today, the number of cancer patients throughout the world is increasing alarmingly and as per the World Health Organisation (WHO) data and statistics the prediction for the year 2020 will be 15 million new cases as compared to only 10 million cases in year 2000 leaving us dumbfounded. A lot of effort has been put in by researchers and scientists over decades to find drugs helpful in the treatment of cancers for the benefit of patients—The latest being the Poly ADP-ribose polymerase (PARP) and the Poly ADP-ribose glycohydrolase (PARG) inhibitors. This review highlights their mechanism of action under the rationale of their use and current development in the field of cancer.